- Home
- RFI vs OTLK Comparison
RFI vs OTLK Comparison
Compare RFI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFI | OTLK |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.7M | 249.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RFI | OTLK |
|---|---|---|
| Price | $11.44 | $1.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 110.8K | ★ 12.3M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.78 | $0.16 |
| 52 Week High | $12.17 | $3.39 |
Technical Indicators
Market Signals| Indicator | RFI | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 63.73 |
| Support Level | $10.94 | $1.60 |
| Resistance Level | $11.73 | $1.88 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 69.84 | 55.59 |
Price Performance
Historical ComparisonAbout RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.